Lung cancer screening

Ryan Clay, Fabien Maldonado, Eric Edell

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [1, 2]. In spite of the major advances achieved in lung cancer diagnosis, medical and surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16% [3]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65%, 88%, and 99%, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.

Original languageEnglish (US)
Title of host publicationInterventions in Pulmonary Medicine
PublisherSpringer International Publishing
Pages313-322
Number of pages10
ISBN (Electronic)9783319580364
ISBN (Print)9783319580357
DOIs
StatePublished - Jan 1 2017

Fingerprint

Early Detection of Cancer
Lung Neoplasms
Screening
Statistics
Colonic Neoplasms
Neoplasms
Palliative Care
Prostate
Prostatic Neoplasms
Breast
Survival Rate
Breast Neoplasms
Survival
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Clay, R., Maldonado, F., & Edell, E. (2017). Lung cancer screening. In Interventions in Pulmonary Medicine (pp. 313-322). Springer International Publishing. https://doi.org/10.1007/978-3-319-58036-4_19

Lung cancer screening. / Clay, Ryan; Maldonado, Fabien; Edell, Eric.

Interventions in Pulmonary Medicine. Springer International Publishing, 2017. p. 313-322.

Research output: Chapter in Book/Report/Conference proceedingChapter

Clay, R, Maldonado, F & Edell, E 2017, Lung cancer screening. in Interventions in Pulmonary Medicine. Springer International Publishing, pp. 313-322. https://doi.org/10.1007/978-3-319-58036-4_19
Clay R, Maldonado F, Edell E. Lung cancer screening. In Interventions in Pulmonary Medicine. Springer International Publishing. 2017. p. 313-322 https://doi.org/10.1007/978-3-319-58036-4_19
Clay, Ryan ; Maldonado, Fabien ; Edell, Eric. / Lung cancer screening. Interventions in Pulmonary Medicine. Springer International Publishing, 2017. pp. 313-322
@inbook{3ba141151d0847ad8a36cd625f24140c,
title = "Lung cancer screening",
abstract = "Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [1, 2]. In spite of the major advances achieved in lung cancer diagnosis, medical and surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16{\%} [3]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65{\%}, 88{\%}, and 99{\%}, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.",
author = "Ryan Clay and Fabien Maldonado and Eric Edell",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-58036-4_19",
language = "English (US)",
isbn = "9783319580357",
pages = "313--322",
booktitle = "Interventions in Pulmonary Medicine",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Lung cancer screening

AU - Clay, Ryan

AU - Maldonado, Fabien

AU - Edell, Eric

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [1, 2]. In spite of the major advances achieved in lung cancer diagnosis, medical and surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16% [3]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65%, 88%, and 99%, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.

AB - Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [1, 2]. In spite of the major advances achieved in lung cancer diagnosis, medical and surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16% [3]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65%, 88%, and 99%, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.

UR - http://www.scopus.com/inward/record.url?scp=85042483501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042483501&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-58036-4_19

DO - 10.1007/978-3-319-58036-4_19

M3 - Chapter

AN - SCOPUS:85042483501

SN - 9783319580357

SP - 313

EP - 322

BT - Interventions in Pulmonary Medicine

PB - Springer International Publishing

ER -